Renaissance Capital logo

US IPO Week Ahead: At least 7 sizable IPOs teed up in one of the busiest weeks in four years

January 30, 2026
Week Ahead

Seven IPOs raising at least $100 million are currently scheduled for the week ahead, in what could be one of the busiest weeks for sizable offerings since 2021. Notably, only one other week over the past four years has produced seven $100 million-plus IPOs, underscoring the renewed depth in issuance even as IPO investors remain selective. An eighth IPO (SGP) is tentatively scheduled for the month, and could also list this week.

The week ahead features emerging themes including a biotech rebound, a consumer comeback, and the first billion-dollar IPO of the year. However, stay tuned on whether a possible US government shutdown impedes their listing plans.

Veradermics Therapeutics plans to raise $200 million at a $509 million market cap. The dermatologist-founded, late clinical-stage biopharmaceutical company is developing an oral, non-hormonal extended-release formulation of minoxidil for male and female pattern hair loss. Veradermics has fully enrolled its Phase 2/3 trial in men and has initiated two additional Phase 3 registration-directed trials in male and female patients to support an NDA, targeting a large, underserved population.

Bob's Discount Furniture plans to raise $370 million at a $2.4 billion market cap. The national omnichannel retailer operates more than 200 showrooms and offers value-focused home furnishings through a tiered pricing strategy. Bob’s serves a broad customer base with a high level of cross-channel engagement and rapid delivery capabilities, bolstered by strong regional revenue concentration and an established multi-state footprint.

Eikon Therapeutics plans to raise $318 million at a $908 million valuation. Led by a team of executives from Merck, the late-stage clinical biopharmaceutical company has raised more than $1 billion privately, and is advancing a pipeline of oncology drug candidates, including a TLR7/8 dual agonist in global Phase 2/3 trials and multiple early-stage programs targeting key cancer indications. Eikon’s diversified clinical portfolio reflects an ambitious push across immuno-oncology and targeted therapy development.

Forgent Power Solutions plans to raise $1.6 billion at an $8.2 billion market cap. The designer and manufacturer of electrical distribution equipment serves data centers, power grids, and industrial facilities with a broad suite of products, including transformers and switchgear. Forgent benefits from a large manufacturing footprint and recent capacity expansion to support growth across energy-intensive end markets, including fast-growing AI data center customers.

Liftoff Mobile plans to raise $762 million at a $5.5 billion market cap. Backed by Blackstone and formed through the merger of Liftoff and Vungle, the company’s AI-powered platform supports mobile app user acquisition and ad monetization across verticals such as gaming, finance, and social media. Its software development kit is integrated into hundreds of thousands of apps, reaching over a billion daily active users. 

Once Upon a Farm plans to raise $209 million at a $724 million market cap. Co-founded by actress Jennifer Garner, the producer of organic, refrigerated food products for babies and children sells its nutritious products through retail and online channels, achieving broad distribution and a significant direct-to-consumer presence. Its portfolio includes cold-pressed pouches and snacks designed for convenience and healthy eating.

AgomAb Therapeutics plans to raise $213 million at an $875 million market cap. The clinical-stage biopharmaceutical company is developing novel disease-modifying therapies for immunology and inflammatory diseases, with a lead oral inhibitor targeting the TGF-β pathway in fibrotic conditions. Its pipeline also includes an inhaled therapy for idiopathic pulmonary fibrosis.  

U.S. IPO Calendar
Issuer
Business
Deal Size
Market Cap
Price Range
Shares Filed
Top
Bookrunners
Veradermics (MANE)
New Haven, CT
$200M
$509M
$14 - $16
13,350,000
Jefferies
Leerink Partners
Phase 3-ready biotech developing therapies for hair loss.
Bob's Discount Furniture (BOBS)
Manchester, CT
$350M
$2,441M
$17 - $19
19,450,000
JP Morgan
Morgan Stanley
Budget retailer of furniture and bedding.
Eikon Therapeutics (EIKN)
Millbrae, CA
$300M
$900M
$16 - $18
17,648,000
JP Morgan
Morgan Stanley
Phase 2 biotech developing in-licensed therapies for immuno-responsive cancers.
Forgent Power Solutions (FPS)
Dayton, MN
$1,512M
$8,220M
$25 - $29
56,000,000
Goldman
Jefferies
Manufactures electrical distribution equipment for data centers and industrial facilities.
Liftoff Mobile (LFTO)
Redwood City, CA
$711M
$5,533M
$26 - $30
25,400,000
Goldman
Jefferies
Provides AI-powered advertising and monetization software for mobile apps.
Once Upon a Farm (OFRM)
Berkeley, CA
$198M
$811M
$17 - $19
10,997,209
Goldman
JP Morgan
Produces organic baby food.
AgomAb Therapeutics (AGMB)
Antwerp, Belgium
$200M
$875M
$15 - $17
12,500,000
JP Morgan
Morgan Stanley
Belgian Phase 2 biotech developing TGFß inhibitors for Crohn's and other fibrotic diseases.
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.

Seven lock-up periods will be expiring in the week ahead. View lock-up expiration dates on the Master Calendar.

IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 1/29/2026, the Renaissance IPO Index was up 1.2% year-to-date, while the S&P 500 was up 1.9%. Renaissance Capital’s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include CoreWeave (CRWV) and Kenvue (KVUE). The Renaissance International IPO Index was up 13.7% year-to-date, while the ACWX was up 6.7%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Kioxia and Galderma.